WOMEN’S-ENTREPRENEURSHIP
13.9.2023 20:19:31 CEST | Business Wire | Press release
In alignment with the 78th session of the United Nations General Assembly, the Women’s Entrepreneurship Accelerator (WEA) is proud to announce a pivotal event spotlighting the pressing gap in financing for women-led businesses. This initiative is a collaborative effort with WEA-participating UN agencies, Mary Kay Global, Yildiz Holding, and the Women Entrepreneurs Act initiative (WE Act) of the Women20 (W20) countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230913108266/en/
Titled “Inclusive Capital: Empowering Women Entrepreneurs on a Global Scale,” the WEA’s event at UNGA78 is a pivotal event spotlighting the pressing gap in financing for women-led businesses and aiming to foster dialogue among stakeholders in the women's entrepreneurship ecosystem. (Credit: Women’s Entrepreneurship Accelerator)
“Inclusive Capital: Empowering Women Entrepreneurs on a Global Scale”
Conference Room 2, United Nations Headquarters, NYC
Thursday 21 September 2023. Time: 6:00 pm – 8:00 pm ET
Register here
The event aims to foster dialogue among stakeholders in the women's entrepreneurship ecosystem. Discussions will revolve around the financial challenges women entrepreneurs face, the significance of inclusive investing, and the need for institutional and corporate entities to adopt a gender-inclusive perspective in their decision-making processes.
“Through the inception of the Women’s Entrepreneurship Accelerator, Mary Kay has helped carve a new path of intervention for the private sector,” said Deborah Gibbins, Chief Operating Officer, and Chief Financial Officer of Mary Kay Inc. “WEA is a groundbreaking partnership vehicle where the United Nations, public and private sectors, civil society organizations, and policy experts work together to transform the world WITH and FOR women entrepreneurs.”
The evening will commence with welcoming remarks from the executive leadership of UN Women followed by an introduction from Fulya Fraser, Chief Growth Officer at Pladis – part of the Yildiz Holding family of companies.
Two panel sessions will delve deep into the topics at hand:
- Accelerating Agenda 2030 through Women Entrepreneurship - Moderated by Virginia Littlejohn, Global Coordinator for Women Entrepreneurs Act (WE Act) designed to drive W20 action and implementation. The session will explore the "Trillion-dollar Opportunity in Supporting Women Entrepreneurs" and the potential economic impact if women-led businesses surmount financial barriers. Esteemed speakers include executive leaders from WEA UN partner agencies.
- Global Action for Women's Entrepreneurship - This session will spotlight major projects and programs in women entrepreneurship, featuring insights from international development leaders like Adriana Carvalho (W20Brazil), Wendy Teleki (World Bank), Marie-Christine Oghly (Femmes Chefs d’ Entreprise Mondiales - FCEM); Catherine Bosshart (Business and Professional Women - BPW), Anne Ravanona (Global InvestHER), Deborah Gibbins, Mary Kay Global, Lamia Kamal-Chaoui (Organisation for Economic Co-operation and Development - OECD).
The event's keynote will be delivered by Shazi Visram, Founder and CEO of Happy Family brands.
Registration is open until Sunday 17 September 2023 at 11:59 p.m. ET for in-person attendance at the UN Headquarters, NYC. For those unable to attend, the event will be streamed live on the United Nations Web TV website.
For more information and to register, click here.
About the Women’s Entrepreneurship Accelerator
The Women’s Entrepreneurship Accelerator (WEA) is a multi-stakeholder partnership on women’s entrepreneurship established during UNGA 74. It convenes six UN agencies, International Labour Organization (ILO), International Trade Centre (ITC), International Telecommunication Union (ITU), United Nations Development Programme (UNDP), United Nations Global Compact (UNGC), UN Women and Mary Kay Inc. to empower 5 million women entrepreneurs by 2030.
The ultimate goal of the initiative is to maximize the development impact of women entrepreneurship in achieving the Sustainable Development Goals (SDGs) by creating an enabling eco-system for women entrepreneurs around the world. The Accelerator exemplifies the transformational power of a multi-partnership of unique magnitude to harness the potential of women entrepreneurs.
Learn more at we-accelerate. Follow us: Twitter/X (We_Accelerator), Instagram (@we_accelerator), Facebook (@womensentrepreneurshipaccelerator), LinkedIn (@womensentrepreneurshipaccelerator)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230913108266/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom